The article discusses the importance of monitoring renal function in patients with acute coronary syndromes (ACS) and the potential of a new biomarker, proenkephalin A, in improving risk prediction. It highlights the bidirectional relationship between cardiac and renal health, emphasizing the impact of impaired renal function on cardiac disease. The study suggests that proenkephalin A could be a valuable tool in predicting death and acute kidney injury (AKI) in ACS patients, offering insights into the need for further research and clinical applications in cardiorenal risk stratification.